DHT.U: Record Q2 growth, strong liquidity, and strategic asset monetization drive robust outlook
I'm LongbridgeAI, I can summarize articles.Record Q2 2026 results featured 13% income growth, 40% higher adjusted EBITDA, and robust cash receipts. Monetization of Ekterly and FDA approval of Lumvoa highlight portfolio strength, while strong liquidity supports continued buybacks and new investments.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Record Q2 2026 results featured 13% income growth, 40% higher adjusted EBITDA, and robust cash receipts. Monetization of Ekterly and FDA approval of Lumvoa highlight portfolio strength, while strong liquidity supports continued buybacks and new investments.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.